ClinicalTrials.gg
RecruitingNCT07804186Updated Nov 12, 2026

Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma

A Phase 3 interventional study of Darovasertib and Crizotinib (Xalkori) in Uveal Melanoma, sponsored by IDEAYA Biosciences. Recruiting at 29 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by IDEAYA Biosciences · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 12, 2026First sites in 4 new countriesSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 190 studies in Uveal Melanoma with a site in United States — 25 open to participants now, 50 under way, 7 of them phase 3. Uveal Melanoma · United States.

Planned enrollment
3rd of 162
450 · median 36
Started
2026
with 5 others
Phase 3
10 of 190
3 open now
Primary completion
2034-03
later than 49 of 49 live
Registered
189th of 190
by date
Lead sponsor
5 of 190
IDEAYA Biosciences

Among the 190 studies in Uveal Melanoma with a site in United States, this one is the 3rd largest by planned enrollment of the 162 interventional ones that give a count, is one of 6 that started in 2026, is one of 10 in phase 3, reaches primary completion later than 49 of the 49 other live ones, and was the 189th registered.

Uveal Melanoma

281 studies on the registry are indexed under Uveal Melanoma; 50 are open to participants now.

Browse Uveal Melanoma studies →

Open to participants now

25 of the 190 studies in Uveal Melanoma with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 42 Uveal Melanoma studies recruiting now, 35 (83%) set no upper age limit and 4 (10%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 190 studies in Uveal Melanoma with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, multi-center, open-label study of adjuvant darovasertib in participants with non-metastatic uveal melanoma (OptimUM-11)

Read the detailed description

This study will enroll participants who are at high-risk for metastatic disease and who have completed primary local therapy (i.e., plaque brachytherapy, proton beam radiation, or enucleation) for their UM without evidence of active local or metastatic disease after this treatment.

The Treatment Arm will have participants who have completed PLT and will receive darovasertib + crizotinib.

The Observation Arm participants will not receive darovasertib + crizotinib but will be observed and followed for disease recurrence and survival (Control Arm)

Participants in both arms will be followed for up to five years to assess longer term outcomes such as tumor recurrence and survival.

03

Conditions studied

  • Uveal Melanoma

Browse trials for

Keywords

  • Uveal Melanoma
  • plaque brachytherapy
  • enucleation
  • proton beam
  • Adjuvant
  • Darovasertib
  • IDE 196
  • Ocular Melanoma
  • Choroidal Melanoma
  • Ocular Oncology
  • Protein Kinase C
  • GNAQ
  • GNA11
  • Crizotinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary Uveal Melanoma, classified as high-risk of relapse (AJCC Stage II or Stage 3)
  • Completed primary local therapy (enucleation, proton beam therapy, plaque brachytherapy)
  • performance status of 0 or 1
  • Adequate organ function
  • Age 18 or older
  • Written and ability to comply
  • Primary local therapy completed within 120 days before C1D1/randomization.
  • requirements

Exclusion criteria

Exclusion Criteria:

  • Previous systemic treatment for Uveal Melanoma
  • Clinical or radiological evidence of UM
  • Concurrent malignant disease with the following exceptions: that were treated curatively and have not recurred within 2 years prior to randomization, completely resected basal cell and squamous cell skin cancers, any malignancy considered to be indolent and never required systemic therapy, and any type of carcinoma in situ receiving curative therapy (resection)
  • Known AIDS related illness
  • History of interstitial lung disease, active pneumonitis, or history of noninfectious pneumonitis requiring
  • History of syncope may be exclusionary, but will be reviewed on a case-by-case basis
  • Active or C infection
  • Any gastrointestinal condition (eg, inflammatory bowel disease, major gastric or intestinal surgery) that could affect absorption or ability to swallow
  • Females who are pregnant or breastfeeding
  • Impaired cardiac function
  • History of stroke within the last 6 months of randomization
  • Ongoing use of medication use for infections, other antineoplastic therapies, or other prohibited medications, including medications that interact with the metabolism of darovasertib+crizotinib
  • allergy to mammalian meat products or gelatin
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    Treatment

    Participant Group/Arm: Treatment combination dose of IDE196 + crizotinib will be tested

    Drug: Darovasertib · Drug: Crizotinib (Xalkori)

  • No intervention
    Observation

    Participant Group/Arm: Observation Standard of care observation \& follow-up (no treatment)

Interventions

06

What researchers measure

Primary outcomes

  1. Median relapse-free survival

    Time to local recurrence or metastatic disease per Blinded Independent Central Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)

    Time frame: Approximately 5 years

Secondary outcomes

  1. Median metastasis-free survival

    Median MFS, defined as the time from randomization to the date of metastatic disease (outside of the eye or orbit) by BICR per RECIST v 1.1

    Time frame: Approximately 5 years

  2. Overall survival

    Overall survival with darovasertib + crizotinib versus observation in participants who have completed PLT for primary UM with no evidence of metastatic disease who are at high-risk for recurrence

    Time frame: Approximately 5 years

  3. Median UM specific survival

    Median UM specific survival defined as the time from randomization to the date of death due to UM

    Time frame: Approximately 5 years

  4. Median metastasis-free survival

    Median MFS, defined as the time from randomization to the date of metastatic disease (outside of the eye or orbit) as assessed by investigator

    Time frame: Approximately 5 years

  5. Safety, and severity of occurrence of adverse events (AEs) as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) V6.0 or later

    To assess safety and tolerability of darovasertib + crizotinib in participants who have completed PLT for primary UM

    Time frame: Approximately 3 years

  6. Change from baseline over time and across Treatment Arms as measured by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core-30 (QLQ-C30)

    Compare quality of life outcomes of darovasertib + crizotinib versus observation in participants who have completed PLT for primary UM

    Time frame: Approximately 5 years

  7. Recurrence-free suvival

    Compare RFS of darovasertib + crizotinib versus observation in participants who have completed PLT for primary UM with no evidence of metastatic disease and who are at high-risk for recurrence

    Time frame: Approximately 5 years

  8. Metastasis-Free Survival

    Compare MFS of darovasertib + crizotinib versus observation in participants who have completed PLT for primary UM with no evidence of metastatic disease and who are at high-risk for recurrence

    Time frame: Approximately 5 years

  9. Median Local Recurrence-Free Survival

    Compare local RFS (LRFS) of darovasertib + crizotinib versus observation in participants who have completed PLT for primary UM with no evidence of metastatic disease and who are at high-risk for recurrence

    Time frame: Approximately 5 years

  10. Change from baseline over time and across Treatment Arms as measured by European Quality of Life Questionnaire EQ-5D-5L.

    Compare quality of life outcomes of darovasertib + crizotinib versus observation in participants who have completed PLT for primary UM

    Time frame: [Time Frame: Approximately 5 years]

  11. Change from baseline over time and across Treatment Arms as measured by EORTC Oncology Quality of Life Questionnaire Ophthalmic-30 (EORTC QLQ-OPT30)

    Compare quality of life outcomes of darovasertib + crizotinib versus observation in participants who have completed PLT for primary UM

    Time frame: [Time Frame: Approximately 5 years]

07

Study locations

6 of 29 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Mar 2034, 90 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2026
First posted
Sep 4, 2026
StartActual
Sep 4, 2026
Primary completionEst.
Mar 2034
CompletionEst.
Apr 2034
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
16 sites added — first sites in Australia, Israel, Switzerland and United Kingdom. 2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Duke Cancer Center · Raleigh, United StatesNot yet recruiting→Recruiting
  • Cleveland Clinic · Cleveland, United StatesNot yet recruiting→Recruiting
Show 16 added (9 United States, 2 Australia, 2 Israel, 2 United Kingdom, 1 Switzerland)
  • Angeles Clinic · Los Angeles, United States
  • University of California, San Diego · San Diego, United States
  • Sutter Health CPMC · San Francisco, United States
  • University of California, San Francisco · San Francisco, United States
  • University of Miami · Miami, United States
  • USF Health Eye Institute · Tampa, United States
  • Columbia University - Herbert Irving Comprehensive Cancer Center · New York, United States
  • The University of Texas Southwestern Medical Center · Dallas, United States
  • UT MD Anderson Cancer Center · Houston, United States
  • Princess Alexandra Hospital · Woolloongabba, Australia
  • Alfred Health · Melbourne, Australia
  • Hadassah Medical Center · Jerusalem, Israel
  • Sheba Medical Center · Ramat Gan, Israel
  • University of Zurich Hospital · Zurich, Switzerland
  • Beatson West of Scotland Cancer Centre · Glasgow, United Kingdom
  • Mount Vernon Hospital · Northwood, United Kingdom
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    16 sites added — first sites in Australia, Israel, Switzerland and United Kingdom. 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Duke Cancer Center · Raleigh, United StatesNot yet recruiting→Recruiting
    • Cleveland Clinic · Cleveland, United StatesNot yet recruiting→Recruiting
    Show 16 added (9 United States, 2 Australia, 2 Israel, 2 United Kingdom, 1 Switzerland)
    • Angeles Clinic · Los Angeles, United States
    • University of California, San Diego · San Diego, United States
    • Sutter Health CPMC · San Francisco, United States
    • University of California, San Francisco · San Francisco, United States
    • University of Miami · Miami, United States
    • USF Health Eye Institute · Tampa, United States
    • Columbia University - Herbert Irving Comprehensive Cancer Center · New York, United States
    • The University of Texas Southwestern Medical Center · Dallas, United States
    • UT MD Anderson Cancer Center · Houston, United States
    • Princess Alexandra Hospital · Woolloongabba, Australia
    • Alfred Health · Melbourne, Australia
    • Hadassah Medical Center · Jerusalem, Israel
    • Sheba Medical Center · Ramat Gan, Israel
    • University of Zurich Hospital · Zurich, Switzerland
    • Beatson West of Scotland Cancer Centre · Glasgow, United Kingdom
    • Mount Vernon Hospital · Northwood, United Kingdom
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07804186
Lead sponsor
IDEAYA Biosciences
Responsible party
Sponsor
First posted
Sep 4, 2026
Start date
Sep 4, 2026
Primary completion
Mar 2034 (estimated)
Completion
Apr 2034 (estimated)
Last update
Nov 12, 2026

Study contacts

IDEAYA Clinical Trials
Contact
IDEAYAClinicalTrials@ideayabio.com
+1-855-433-2246
Holger Thurm
Contact
hthurm@ideayabio.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Darovasertib · Crizotinib

Start the discussion